Adtalem Global Education Inc. (NYSE:CVSA - Get Free Report) CAO Manjunath Gangadharan sold 1,802 shares of the business's stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $137.18, for a total transaction of $247,198.36. Following the transaction, the chief accounting officer owned 5,083 shares in the company, valued at approximately $697,285.94. This trade represents a 26.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Adtalem Global Education Stock Down 4.2%
NYSE CVSA opened at $134.71 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $4.59 billion, a PE ratio of 19.13, a P/E/G ratio of 1.04 and a beta of 0.62. Adtalem Global Education Inc. has a 52-week low of $86.97 and a 52-week high of $156.26. The business's 50-day moving average price is $127.39.
Adtalem Global Education (NYSE:CVSA - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $2.09 earnings per share for the quarter, beating analysts' consensus estimates of $1.90 by $0.19. Adtalem Global Education had a return on equity of 20.88% and a net margin of 12.87%.The company had revenue of $501.38 million for the quarter. Adtalem Global Education has set its FY 2027 guidance at 8.900-9.150 EPS. On average, equities research analysts expect that Adtalem Global Education Inc. will post 9 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new position in Adtalem Global Education stock. Kendall Capital Management purchased a new stake in shares of Adtalem Global Education Inc. (NYSE:CVSA - Free Report) in the second quarter, according to its most recent filing with the SEC. The firm purchased 11,622 shares of the company's stock, valued at approximately $1,449,000. 98.84% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of research firms recently weighed in on CVSA. Barrington Research restated an "outperform" rating and issued a $170.00 price target on shares of Adtalem Global Education in a research note on Monday, June 8th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Adtalem Global Education in a research report on Wednesday, August 19th. Wall Street Zen raised Adtalem Global Education from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Finally, Truist Financial boosted their target price on shares of Adtalem Global Education from $130.00 to $140.00 and gave the stock a "buy" rating in a research report on Monday, May 11th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $155.00.
Get Our Latest Stock Analysis on Adtalem Global Education
About Adtalem Global Education
(
Get Free Report)
Adtalem Global Education (NYSE: CVSA) is a provider of higher education and workforce solutions focused primarily on programs that prepare students for professional careers in healthcare, medicine, veterinary medicine and related fields. The company operates campus-based and online degree programs, continuing professional education, clinical training and exam-preparation offerings designed to support students seeking licensure and employment in regulated professions.
Adtalem’s portfolio includes institution brands that deliver undergraduate, graduate and professional training across nursing, medicine, veterinary medicine and allied health disciplines.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
